Multiple myeloma (MM) is a hematological malignancy worldwide in urgent need for novel therapeutic strategies. Since Velcade (bortezomib) was approved for the treatment of relapsed/refractory MM in 2003, we have seen considerable improvement in extending MM patient survival. However, most patients a...
Flag antibody was used for immunoprecipitation, and cd229-OE partial binding protein was searched by protein spectrum in CD229-OE multiple myeloma cell line, and its interaction was analyzed.
